Home > Cardiology > ESC 2022 > First RCT evidence for use of AI in daily practice

First RCT evidence for use of AI in daily practice

Presented By
Dr David Ouyang, Cedars-Sinai Smidt Heart Institute, CA, USA
Conference
ESC 2022
Trial
EchoNet-RCT
In the first and only randomised-controlled trial of its kind, initial assessment of left ventricular ejection fraction (LVEF) by artificial intelligence (AI) was non-inferior and superior to initial sonographer assessment. After blinded review of initial LVEF assessment, cardiologists were less likely to substantially change their final report with initial AI assessment than sonographer assessment. Furthermore, AI-guided assessment took less time for cardiologists to overread, and was more consistent in test-retest modelling. While tremendous progress in applying AI to cardiology has been made, no blinded randomised studies have yet provided high-level evidence comparing its use to standard-of-care sonographer assessments. The EchoNet-RCT (NCT05140642) met that challenge; the findings were reported by Dr David Ouyang (Cedars-Sinai Smidt Heart Institute, C...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on